Drug Monograph

Drug/Drug Class: **Adzenys ER® (amphetamine) extended release suspension /ADHD**
Prepared for: MO HealthNet
Prepared by: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Adzenys ER® is available in an extended-release oral suspension containing 1.25 mg amphetamine per ml.
Manufacturer:	Neos Therapeutics Brands, LLC, Grand Prairie, TX 75050
Indications:	Adzenys ER® is indicated for the treatment of Attention Deficit Hyperactivity Disorder in patients 6 years and older.
Costs:	$1.42 per ml of Adzenys ER®. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the new ADHD PDL as non-preferred and to the current psychotropic polypharmacy clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-Preferred ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer PharmD
Date: May 18, 2018